FDIME Best Research Abstracts Awards ECIM 2021 (March 20, 2021)

During the virtual ECIM 2021 three abstracts were awarded as FDIME best research abstracts. A jury consisting of Jan Willem Elte (FDIME Secretary General), Ramon Pujol (FDIME Vice President), Nicola Montana (Past EFIM President and FDIME Board member) and Runolfur Palsson (Past-past EFIM President and FDIME Board member) made the definitive selection.

The following three abstracts received the awards:

  1. 76 IMPAIRED HOST ANTIVIRAL TH1 AND CD8 RESPONSE IN HIGHLY INFLAMMATORY SARS-COV-2 PATIENTS
    Dr Janine Rupp from Austria
    The T cell composition, activation and proliferation in patients with severe (n=8) or critical (n=12) Covid 19 and matched healthy controls ( 2 per Covid patient) were assessed.
    Beside lymphopenia several abnormal Th cell patterns were identified and also CD4+ and CD8+ cells amongst others differed from healthy controls suggesting active anti-viral T cell defense.
    Conclusion: the data suggest that SARS-CoV-2 induced CRS ( cytokine release syndrome) may impair viral clearance by blunting the antiviral T-cell response.
  2. 115 EFFICACY OF CDSS IN IMPROVING ANTI-RESORPTIVE BONE PROTECTIVE THERAPY AMONGST ORTHOGERIATRIC INPATIENTS: A COMPARISON STUDY
    Dr Lata Bhandary from Ireland
    Subject of the study was to compare the proportion of patients commenced on ABPT ( anti-resorptive bone protective therapy) following the introduction of a clinical decision support system (CDDS) to support appropriate ABPT prescribimg by non-specialists.
    An orthogeriatric patient cohort before (2019) and after (2020) was studied. In 2019 31 % (55/178) did not receive orthogeriatric specialist input and only 27 % (15 of 55) had ABPT. In 2020 17 % (32/185) did not receive specialist input, however, 44 % (14/32) were commenced on ABPT.
    Overall more patients were prescribed ABPT in 2020 (78 %) than in 2019 (55 %).
    Conclusion: a CDDS improves ABPT prescribing and may reduce specialist appointments, long-term mortality and future health costs.
  3. 1072 GLUTEN-SPECIFIC CD4+ T CELLS EXPRESS A DISTINCT SET OF MARKERS AFTER GLUTEN CHALLENGE THAT CORRELATE WELL ON THE TRANSCRIPTOMIC AND PHENOTYPIC LEVEL
    Dr Stephanie Zühlke from Norway
    After a 3-day gluten challenge in CeD (Coeliac Disease) blood was sampled after 6 days. A clear increase in gut-homing gluten-specific effector-memory (CD4) T cells were observed in all 6 patients. Transcriptome analysis revealed 94 DE genes coding for cell surface markers, phenotypically similar with gluten-specific T-cells. So the gluten-specific cells from blood after gluten challenge may serve as an alternative outcome measure in clinical drug trials.
    In short: gluten-specific CD4+ T cells express a distinct set of markers after gluten challenge.